nodes	percent_of_prediction	percent_of_DWPC	metapath
Carvedilol—GJA1—malignant glioma	0.303	0.45	CbGaD
Carvedilol—HIF1A—malignant glioma	0.23	0.341	CbGaD
Carvedilol—VEGFA—malignant glioma	0.0925	0.137	CbGaD
Carvedilol—PTGS1—malignant glioma	0.0488	0.0724	CbGaD
Carvedilol—CYP1A2—Carmustine—malignant glioma	0.029	0.569	CbGbCtD
Carvedilol—CYP3A4—Temozolomide—malignant glioma	0.0219	0.43	CbGbCtD
Carvedilol—SELE—umbilical vein—malignant glioma	0.00521	0.0696	CbGeAlD
Carvedilol—VCAM1—umbilical vein—malignant glioma	0.00479	0.064	CbGeAlD
Carvedilol—NPPB—blood vessel—malignant glioma	0.00337	0.045	CbGeAlD
Carvedilol—SELE—endothelium—malignant glioma	0.00247	0.033	CbGeAlD
Carvedilol—SELE—blood vessel—malignant glioma	0.00228	0.0304	CbGeAlD
Carvedilol—Leg edema—Temozolomide—malignant glioma	0.00228	0.0342	CcSEcCtD
Carvedilol—VCAM1—endothelium—malignant glioma	0.00227	0.0303	CbGeAlD
Carvedilol—HIF1A—endothelium—malignant glioma	0.00219	0.0292	CbGeAlD
Carvedilol—GJA1—endothelium—malignant glioma	0.00212	0.0283	CbGeAlD
Carvedilol—VCAM1—blood vessel—malignant glioma	0.0021	0.028	CbGeAlD
Carvedilol—HIF1A—blood vessel—malignant glioma	0.00202	0.0269	CbGeAlD
Carvedilol—GJA1—blood vessel—malignant glioma	0.00196	0.0261	CbGeAlD
Carvedilol—Clotting—Temozolomide—malignant glioma	0.00172	0.0258	CcSEcCtD
Carvedilol—Paresis—Temozolomide—malignant glioma	0.00168	0.0252	CcSEcCtD
Carvedilol—Traumatic liver injury—Temozolomide—malignant glioma	0.00165	0.0247	CcSEcCtD
Carvedilol—Interstitial pneumonia—Temozolomide—malignant glioma	0.00127	0.0191	CcSEcCtD
Carvedilol—HIF1A—embryo—malignant glioma	0.0012	0.0161	CbGeAlD
Carvedilol—GJA1—embryo—malignant glioma	0.00117	0.0156	CbGeAlD
Carvedilol—VCAM1—retina—malignant glioma	0.00111	0.0148	CbGeAlD
Carvedilol—HIF1A—brainstem—malignant glioma	0.0011	0.0147	CbGeAlD
Carvedilol—GJA1—brainstem—malignant glioma	0.00107	0.0143	CbGeAlD
Carvedilol—HIF1A—retina—malignant glioma	0.00106	0.0142	CbGeAlD
Carvedilol—Cerebration impaired—Temozolomide—malignant glioma	0.00104	0.0157	CcSEcCtD
Carvedilol—GJA1—retina—malignant glioma	0.00103	0.0138	CbGeAlD
Carvedilol—HIF1A—telencephalon—malignant glioma	0.000978	0.0131	CbGeAlD
Carvedilol—GJA1—telencephalon—malignant glioma	0.000949	0.0127	CbGeAlD
Carvedilol—Hypokinesia—Carmustine—malignant glioma	0.00094	0.0141	CcSEcCtD
Carvedilol—Paranoia—Carmustine—malignant glioma	0.000931	0.014	CcSEcCtD
Carvedilol—NPPB—central nervous system—malignant glioma	0.00093	0.0124	CbGeAlD
Carvedilol—NDUFC2—retina—malignant glioma	0.000898	0.012	CbGeAlD
Carvedilol—Interstitial lung disease—Carmustine—malignant glioma	0.000896	0.0135	CcSEcCtD
Carvedilol—SELE—medulla oblongata—malignant glioma	0.000868	0.0116	CbGeAlD
Carvedilol—Interstitial lung disease—Temozolomide—malignant glioma	0.000866	0.013	CcSEcCtD
Carvedilol—Lung disorder—Temozolomide—malignant glioma	0.000866	0.013	CcSEcCtD
Carvedilol—NDUFC2—telencephalon—malignant glioma	0.000826	0.011	CbGeAlD
Carvedilol—VCAM1—medulla oblongata—malignant glioma	0.000799	0.0107	CbGeAlD
Carvedilol—SELE—midbrain—malignant glioma	0.000794	0.0106	CbGeAlD
Carvedilol—Coagulopathy—Temozolomide—malignant glioma	0.000788	0.0118	CcSEcCtD
Carvedilol—Hyperaesthesia—Temozolomide—malignant glioma	0.000781	0.0117	CcSEcCtD
Carvedilol—SELE—spinal cord—malignant glioma	0.000774	0.0103	CbGeAlD
Carvedilol—HIF1A—medulla oblongata—malignant glioma	0.000769	0.0103	CbGeAlD
Carvedilol—VEGFA—telencephalon—malignant glioma	0.000749	0.01	CbGeAlD
Carvedilol—GJA1—medulla oblongata—malignant glioma	0.000746	0.00995	CbGeAlD
Carvedilol—Gamma-glutamyltransferase increased—Temozolomide—malignant glioma	0.000745	0.0112	CcSEcCtD
Carvedilol—NPPB—brain—malignant glioma	0.000738	0.00986	CbGeAlD
Carvedilol—VCAM1—midbrain—malignant glioma	0.00073	0.00975	CbGeAlD
Carvedilol—Liver injury—Temozolomide—malignant glioma	0.000729	0.0109	CcSEcCtD
Carvedilol—Accidental injury—Carmustine—malignant glioma	0.000717	0.0108	CcSEcCtD
Carvedilol—VCAM1—spinal cord—malignant glioma	0.000712	0.00951	CbGeAlD
Carvedilol—Disturbance in attention—Temozolomide—malignant glioma	0.000708	0.0106	CcSEcCtD
Carvedilol—HIF1A—midbrain—malignant glioma	0.000702	0.00938	CbGeAlD
Carvedilol—Thinking abnormal—Carmustine—malignant glioma	0.000693	0.0104	CcSEcCtD
Carvedilol—HIF1A—spinal cord—malignant glioma	0.000685	0.00915	CbGeAlD
Carvedilol—GJA1—midbrain—malignant glioma	0.000681	0.0091	CbGeAlD
Carvedilol—Viral infection—Temozolomide—malignant glioma	0.000679	0.0102	CcSEcCtD
Carvedilol—Hyperbilirubinaemia—Temozolomide—malignant glioma	0.000674	0.0101	CcSEcCtD
Carvedilol—GJA1—spinal cord—malignant glioma	0.000665	0.00887	CbGeAlD
Carvedilol—NDUFC2—medulla oblongata—malignant glioma	0.000649	0.00866	CbGeAlD
Carvedilol—Hearing impaired—Temozolomide—malignant glioma	0.000644	0.00968	CcSEcCtD
Carvedilol—SELE—central nervous system—malignant glioma	0.000628	0.00839	CbGeAlD
Carvedilol—SELE—cerebellum—malignant glioma	0.000614	0.0082	CbGeAlD
Carvedilol—Phosphatase alkaline increased—Temozolomide—malignant glioma	0.000613	0.00921	CcSEcCtD
Carvedilol—Urinary incontinence—Carmustine—malignant glioma	0.000613	0.0092	CcSEcCtD
Carvedilol—NDUFC2—midbrain—malignant glioma	0.000593	0.00792	CbGeAlD
Carvedilol—Urinary incontinence—Temozolomide—malignant glioma	0.000592	0.00889	CcSEcCtD
Carvedilol—NDUFC2—spinal cord—malignant glioma	0.000579	0.00772	CbGeAlD
Carvedilol—VCAM1—central nervous system—malignant glioma	0.000578	0.00771	CbGeAlD
Carvedilol—Aplastic anaemia—Temozolomide—malignant glioma	0.000576	0.00865	CcSEcCtD
Carvedilol—HIF1A—central nervous system—malignant glioma	0.000556	0.00742	CbGeAlD
Carvedilol—Abnormal vision—Carmustine—malignant glioma	0.000553	0.00831	CcSEcCtD
Carvedilol—Mental disability—Carmustine—malignant glioma	0.000551	0.00827	CcSEcCtD
Carvedilol—HIF1A—cerebellum—malignant glioma	0.000543	0.00725	CbGeAlD
Carvedilol—GJA1—central nervous system—malignant glioma	0.000539	0.0072	CbGeAlD
Carvedilol—Abnormal vision—Temozolomide—malignant glioma	0.000535	0.00803	CcSEcCtD
Carvedilol—Mental disability—Temozolomide—malignant glioma	0.000532	0.00799	CcSEcCtD
Carvedilol—Diabetes mellitus—Carmustine—malignant glioma	0.000529	0.00795	CcSEcCtD
Carvedilol—GJA1—cerebellum—malignant glioma	0.000527	0.00704	CbGeAlD
Carvedilol—VEGFA—spinal cord—malignant glioma	0.000525	0.00701	CbGeAlD
Carvedilol—Swelling—Carmustine—malignant glioma	0.000522	0.00784	CcSEcCtD
Carvedilol—Blood alkaline phosphatase increased—Temozolomide—malignant glioma	0.000512	0.00769	CcSEcCtD
Carvedilol—Injury—Carmustine—malignant glioma	0.000501	0.00753	CcSEcCtD
Carvedilol—SELE—brain—malignant glioma	0.000499	0.00666	CbGeAlD
Carvedilol—Vascular purpura—Temozolomide—malignant glioma	0.000498	0.00747	CcSEcCtD
Carvedilol—Amnesia—Carmustine—malignant glioma	0.00049	0.00736	CcSEcCtD
Carvedilol—ADRA1D—telencephalon—malignant glioma	0.000489	0.00653	CbGeAlD
Carvedilol—Nasal congestion—Temozolomide—malignant glioma	0.000489	0.00734	CcSEcCtD
Carvedilol—Amnesia—Temozolomide—malignant glioma	0.000474	0.00712	CcSEcCtD
Carvedilol—Dermatitis exfoliative—Temozolomide—malignant glioma	0.000472	0.00709	CcSEcCtD
Carvedilol—NDUFC2—central nervous system—malignant glioma	0.000469	0.00627	CbGeAlD
Carvedilol—Hyponatraemia—Carmustine—malignant glioma	0.000462	0.00695	CcSEcCtD
Carvedilol—Purpura—Temozolomide—malignant glioma	0.000462	0.00694	CcSEcCtD
Carvedilol—Gastrointestinal haemorrhage—Carmustine—malignant glioma	0.000461	0.00692	CcSEcCtD
Carvedilol—NDUFC2—cerebellum—malignant glioma	0.000459	0.00613	CbGeAlD
Carvedilol—VCAM1—brain—malignant glioma	0.000459	0.00612	CbGeAlD
Carvedilol—PTGS1—endothelium—malignant glioma	0.00045	0.00601	CbGeAlD
Carvedilol—HIF1A—brain—malignant glioma	0.000441	0.00589	CbGeAlD
Carvedilol—Affect lability—Temozolomide—malignant glioma	0.000438	0.00658	CcSEcCtD
Carvedilol—GJA1—brain—malignant glioma	0.000428	0.00572	CbGeAlD
Carvedilol—Mood swings—Temozolomide—malignant glioma	0.000422	0.00633	CcSEcCtD
Carvedilol—Hypokalaemia—Carmustine—malignant glioma	0.000419	0.0063	CcSEcCtD
Carvedilol—VEGFA—cerebellum—malignant glioma	0.000416	0.00556	CbGeAlD
Carvedilol—PTGS1—blood vessel—malignant glioma	0.000415	0.00554	CbGeAlD
Carvedilol—Dehydration—Temozolomide—malignant glioma	0.000414	0.00622	CcSEcCtD
Carvedilol—Hypokalaemia—Temozolomide—malignant glioma	0.000405	0.00609	CcSEcCtD
Carvedilol—Aspartate aminotransferase increased—Temozolomide—malignant glioma	0.000401	0.00602	CcSEcCtD
Carvedilol—Toxic epidermal necrolysis—Temozolomide—malignant glioma	0.000401	0.00602	CcSEcCtD
Carvedilol—Alanine aminotransferase increased—Temozolomide—malignant glioma	0.000393	0.0059	CcSEcCtD
Carvedilol—Pancytopenia—Carmustine—malignant glioma	0.000378	0.00568	CcSEcCtD
Carvedilol—Sweating increased—Temozolomide—malignant glioma	0.000375	0.00563	CcSEcCtD
Carvedilol—NDUFC2—brain—malignant glioma	0.000373	0.00498	CbGeAlD
Carvedilol—Bronchitis—Temozolomide—malignant glioma	0.00037	0.00556	CcSEcCtD
Carvedilol—Pancytopenia—Temozolomide—malignant glioma	0.000365	0.00549	CcSEcCtD
Carvedilol—Hyperglycaemia—Carmustine—malignant glioma	0.000359	0.00539	CcSEcCtD
Carvedilol—Upper respiratory tract infection—Temozolomide—malignant glioma	0.000358	0.00537	CcSEcCtD
Carvedilol—Pneumonia—Carmustine—malignant glioma	0.000357	0.00536	CcSEcCtD
Carvedilol—ADRB1—telencephalon—malignant glioma	0.000356	0.00475	CbGeAlD
Carvedilol—Pollakiuria—Temozolomide—malignant glioma	0.000355	0.00534	CcSEcCtD
Carvedilol—Erectile dysfunction—Temozolomide—malignant glioma	0.000354	0.00532	CcSEcCtD
Carvedilol—Depression—Carmustine—malignant glioma	0.000354	0.00532	CcSEcCtD
Carvedilol—Photosensitivity reaction—Temozolomide—malignant glioma	0.000351	0.00528	CcSEcCtD
Carvedilol—Weight increased—Temozolomide—malignant glioma	0.00035	0.00526	CcSEcCtD
Carvedilol—Renal failure—Carmustine—malignant glioma	0.000349	0.00524	CcSEcCtD
Carvedilol—Weight decreased—Temozolomide—malignant glioma	0.000348	0.00523	CcSEcCtD
Carvedilol—Hyperglycaemia—Temozolomide—malignant glioma	0.000347	0.00521	CcSEcCtD
Carvedilol—Urinary tract infection—Carmustine—malignant glioma	0.000345	0.00518	CcSEcCtD
Carvedilol—Pneumonia—Temozolomide—malignant glioma	0.000345	0.00518	CcSEcCtD
Carvedilol—Depression—Temozolomide—malignant glioma	0.000342	0.00514	CcSEcCtD
Carvedilol—Stevens-Johnson syndrome—Temozolomide—malignant glioma	0.00034	0.00511	CcSEcCtD
Carvedilol—VEGFA—brain—malignant glioma	0.000338	0.00451	CbGeAlD
Carvedilol—Urinary tract infection—Temozolomide—malignant glioma	0.000333	0.00501	CcSEcCtD
Carvedilol—Sinusitis—Temozolomide—malignant glioma	0.000322	0.00483	CcSEcCtD
Carvedilol—Haemoglobin—Carmustine—malignant glioma	0.00032	0.00481	CcSEcCtD
Carvedilol—Haemorrhage—Carmustine—malignant glioma	0.000319	0.00479	CcSEcCtD
Carvedilol—Hypoaesthesia—Carmustine—malignant glioma	0.000317	0.00476	CcSEcCtD
Carvedilol—ADRA1A—brainstem—malignant glioma	0.000317	0.00423	CbGeAlD
Carvedilol—Oedema peripheral—Carmustine—malignant glioma	0.000314	0.00472	CcSEcCtD
Carvedilol—Haemoglobin—Temozolomide—malignant glioma	0.000309	0.00465	CcSEcCtD
Carvedilol—Haemorrhage—Temozolomide—malignant glioma	0.000308	0.00463	CcSEcCtD
Carvedilol—Visual impairment—Carmustine—malignant glioma	0.000307	0.00461	CcSEcCtD
Carvedilol—Hypoaesthesia—Temozolomide—malignant glioma	0.000306	0.0046	CcSEcCtD
Carvedilol—Pharyngitis—Temozolomide—malignant glioma	0.000306	0.00459	CcSEcCtD
Carvedilol—Urinary tract disorder—Temozolomide—malignant glioma	0.000304	0.00457	CcSEcCtD
Carvedilol—Oedema peripheral—Temozolomide—malignant glioma	0.000303	0.00456	CcSEcCtD
Carvedilol—Urethral disorder—Temozolomide—malignant glioma	0.000302	0.00453	CcSEcCtD
Carvedilol—Visual impairment—Temozolomide—malignant glioma	0.000297	0.00446	CcSEcCtD
Carvedilol—Erythema multiforme—Temozolomide—malignant glioma	0.000291	0.00437	CcSEcCtD
Carvedilol—Tinnitus—Temozolomide—malignant glioma	0.000287	0.00431	CcSEcCtD
Carvedilol—ADRA1B—central nervous system—malignant glioma	0.000284	0.0038	CbGeAlD
Carvedilol—Alopecia—Carmustine—malignant glioma	0.000282	0.00423	CcSEcCtD
Carvedilol—ADRA1A—telencephalon—malignant glioma	0.000281	0.00375	CbGeAlD
Carvedilol—Angiopathy—Temozolomide—malignant glioma	0.000279	0.0042	CcSEcCtD
Carvedilol—ADRA1D—central nervous system—malignant glioma	0.000278	0.00371	CbGeAlD
Carvedilol—Immune system disorder—Temozolomide—malignant glioma	0.000278	0.00418	CcSEcCtD
Carvedilol—Mediastinal disorder—Temozolomide—malignant glioma	0.000277	0.00417	CcSEcCtD
Carvedilol—Malnutrition—Carmustine—malignant glioma	0.000277	0.00417	CcSEcCtD
Carvedilol—Alopecia—Temozolomide—malignant glioma	0.000272	0.00409	CcSEcCtD
Carvedilol—KCNH2—telencephalon—malignant glioma	0.000272	0.00362	CbGeAlD
Carvedilol—Back pain—Carmustine—malignant glioma	0.000268	0.00403	CcSEcCtD
Carvedilol—Malnutrition—Temozolomide—malignant glioma	0.000268	0.00403	CcSEcCtD
Carvedilol—ADRA2C—telencephalon—malignant glioma	0.000268	0.00358	CbGeAlD
Carvedilol—Vision blurred—Carmustine—malignant glioma	0.000261	0.00393	CcSEcCtD
Carvedilol—Back pain—Temozolomide—malignant glioma	0.000259	0.0039	CcSEcCtD
Carvedilol—Anaemia—Carmustine—malignant glioma	0.000256	0.00385	CcSEcCtD
Carvedilol—Vision blurred—Temozolomide—malignant glioma	0.000253	0.00379	CcSEcCtD
Carvedilol—Ill-defined disorder—Temozolomide—malignant glioma	0.000249	0.00374	CcSEcCtD
Carvedilol—Leukopenia—Carmustine—malignant glioma	0.000248	0.00373	CcSEcCtD
Carvedilol—Anaemia—Temozolomide—malignant glioma	0.000248	0.00372	CcSEcCtD
Carvedilol—ABCB1—blood vessel—malignant glioma	0.000246	0.00328	CbGeAlD
Carvedilol—Angioedema—Temozolomide—malignant glioma	0.000245	0.00368	CcSEcCtD
Carvedilol—Malaise—Temozolomide—malignant glioma	0.000242	0.00363	CcSEcCtD
Carvedilol—Vertigo—Temozolomide—malignant glioma	0.000241	0.00362	CcSEcCtD
Carvedilol—Convulsion—Carmustine—malignant glioma	0.00024	0.00361	CcSEcCtD
Carvedilol—Leukopenia—Temozolomide—malignant glioma	0.00024	0.0036	CcSEcCtD
Carvedilol—Hypertension—Carmustine—malignant glioma	0.000239	0.0036	CcSEcCtD
Carvedilol—Palpitations—Temozolomide—malignant glioma	0.000237	0.00356	CcSEcCtD
Carvedilol—Myalgia—Carmustine—malignant glioma	0.000236	0.00355	CcSEcCtD
Carvedilol—Chest pain—Carmustine—malignant glioma	0.000236	0.00355	CcSEcCtD
Carvedilol—Cough—Temozolomide—malignant glioma	0.000234	0.00351	CcSEcCtD
Carvedilol—Convulsion—Temozolomide—malignant glioma	0.000232	0.00349	CcSEcCtD
Carvedilol—Hypertension—Temozolomide—malignant glioma	0.000231	0.00348	CcSEcCtD
Carvedilol—Confusional state—Carmustine—malignant glioma	0.000228	0.00343	CcSEcCtD
Carvedilol—Myalgia—Temozolomide—malignant glioma	0.000228	0.00343	CcSEcCtD
Carvedilol—Arthralgia—Temozolomide—malignant glioma	0.000228	0.00343	CcSEcCtD
Carvedilol—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—malignant glioma	0.000227	0.0034	CcSEcCtD
Carvedilol—Oedema—Carmustine—malignant glioma	0.000226	0.0034	CcSEcCtD
Carvedilol—ADRA1B—brain—malignant glioma	0.000226	0.00301	CbGeAlD
Carvedilol—Discomfort—Temozolomide—malignant glioma	0.000225	0.00339	CcSEcCtD
Carvedilol—Infection—Carmustine—malignant glioma	0.000225	0.00338	CcSEcCtD
Carvedilol—Dry mouth—Temozolomide—malignant glioma	0.000223	0.00335	CcSEcCtD
Carvedilol—Thrombocytopenia—Carmustine—malignant glioma	0.000222	0.00333	CcSEcCtD
Carvedilol—Tachycardia—Carmustine—malignant glioma	0.000221	0.00332	CcSEcCtD
Carvedilol—ADRA1D—brain—malignant glioma	0.000221	0.00295	CbGeAlD
Carvedilol—Confusional state—Temozolomide—malignant glioma	0.000221	0.00331	CcSEcCtD
Carvedilol—Oedema—Temozolomide—malignant glioma	0.000219	0.00329	CcSEcCtD
Carvedilol—Anaphylactic shock—Temozolomide—malignant glioma	0.000219	0.00329	CcSEcCtD
Carvedilol—Infection—Temozolomide—malignant glioma	0.000217	0.00326	CcSEcCtD
Carvedilol—Anorexia—Carmustine—malignant glioma	0.000216	0.00324	CcSEcCtD
Carvedilol—Thrombocytopenia—Temozolomide—malignant glioma	0.000214	0.00322	CcSEcCtD
Carvedilol—ADRA2A—telencephalon—malignant glioma	0.000214	0.00285	CbGeAlD
Carvedilol—KCNH2—medulla oblongata—malignant glioma	0.000213	0.00285	CbGeAlD
Carvedilol—Skin disorder—Temozolomide—malignant glioma	0.000212	0.00319	CcSEcCtD
Carvedilol—Hypotension—Carmustine—malignant glioma	0.000212	0.00318	CcSEcCtD
Carvedilol—Hyperhidrosis—Temozolomide—malignant glioma	0.000211	0.00318	CcSEcCtD
Carvedilol—ADRA2C—medulla oblongata—malignant glioma	0.00021	0.00281	CbGeAlD
Carvedilol—CYP2E1—telencephalon—malignant glioma	0.000209	0.00279	CbGeAlD
Carvedilol—Anorexia—Temozolomide—malignant glioma	0.000209	0.00313	CcSEcCtD
Carvedilol—Musculoskeletal discomfort—Carmustine—malignant glioma	0.000206	0.0031	CcSEcCtD
Carvedilol—Insomnia—Carmustine—malignant glioma	0.000205	0.00308	CcSEcCtD
Carvedilol—Paraesthesia—Carmustine—malignant glioma	0.000203	0.00305	CcSEcCtD
Carvedilol—ADRB1—central nervous system—malignant glioma	0.000202	0.0027	CbGeAlD
Carvedilol—Dyspnoea—Carmustine—malignant glioma	0.000202	0.00303	CcSEcCtD
Carvedilol—PTGS1—telencephalon—malignant glioma	0.000201	0.00269	CbGeAlD
Carvedilol—Somnolence—Carmustine—malignant glioma	0.000201	0.00302	CcSEcCtD
Carvedilol—Musculoskeletal discomfort—Temozolomide—malignant glioma	0.000199	0.00299	CcSEcCtD
Carvedilol—Insomnia—Temozolomide—malignant glioma	0.000198	0.00297	CcSEcCtD
Carvedilol—Decreased appetite—Carmustine—malignant glioma	0.000197	0.00296	CcSEcCtD
Carvedilol—Paraesthesia—Temozolomide—malignant glioma	0.000196	0.00295	CcSEcCtD
Carvedilol—Gastrointestinal disorder—Carmustine—malignant glioma	0.000195	0.00294	CcSEcCtD
Carvedilol—Dyspnoea—Temozolomide—malignant glioma	0.000195	0.00293	CcSEcCtD
Carvedilol—KCNH2—midbrain—malignant glioma	0.000195	0.0026	CbGeAlD
Carvedilol—Somnolence—Temozolomide—malignant glioma	0.000194	0.00292	CcSEcCtD
Carvedilol—Constipation—Carmustine—malignant glioma	0.000194	0.00291	CcSEcCtD
Carvedilol—Pain—Carmustine—malignant glioma	0.000194	0.00291	CcSEcCtD
Carvedilol—Dyspepsia—Temozolomide—malignant glioma	0.000193	0.00289	CcSEcCtD
Carvedilol—ADRA2C—midbrain—malignant glioma	0.000192	0.00257	CbGeAlD
Carvedilol—KCNH2—spinal cord—malignant glioma	0.00019	0.00254	CbGeAlD
Carvedilol—Decreased appetite—Temozolomide—malignant glioma	0.00019	0.00286	CcSEcCtD
Carvedilol—Gastrointestinal disorder—Temozolomide—malignant glioma	0.000189	0.00284	CcSEcCtD
Carvedilol—Fatigue—Temozolomide—malignant glioma	0.000189	0.00283	CcSEcCtD
Carvedilol—ADRA2C—spinal cord—malignant glioma	0.000188	0.00251	CbGeAlD
Carvedilol—Constipation—Temozolomide—malignant glioma	0.000187	0.00281	CcSEcCtD
Carvedilol—Pain—Temozolomide—malignant glioma	0.000187	0.00281	CcSEcCtD
Carvedilol—CYP2D6—brainstem—malignant glioma	0.000187	0.00249	CbGeAlD
Carvedilol—Feeling abnormal—Carmustine—malignant glioma	0.000187	0.0028	CcSEcCtD
Carvedilol—Gastrointestinal pain—Carmustine—malignant glioma	0.000185	0.00278	CcSEcCtD
Carvedilol—Feeling abnormal—Temozolomide—malignant glioma	0.00018	0.00271	CcSEcCtD
Carvedilol—Abdominal pain—Carmustine—malignant glioma	0.000179	0.00269	CcSEcCtD
Carvedilol—Body temperature increased—Carmustine—malignant glioma	0.000179	0.00269	CcSEcCtD
Carvedilol—Gastrointestinal pain—Temozolomide—malignant glioma	0.000179	0.00269	CcSEcCtD
Carvedilol—Urticaria—Temozolomide—malignant glioma	0.000174	0.00261	CcSEcCtD
Carvedilol—Body temperature increased—Temozolomide—malignant glioma	0.000173	0.0026	CcSEcCtD
Carvedilol—Abdominal pain—Temozolomide—malignant glioma	0.000173	0.0026	CcSEcCtD
Carvedilol—ADRA2A—medulla oblongata—malignant glioma	0.000168	0.00224	CbGeAlD
Carvedilol—Hypersensitivity—Carmustine—malignant glioma	0.000167	0.00251	CcSEcCtD
Carvedilol—CYP2D6—telencephalon—malignant glioma	0.000166	0.00221	CbGeAlD
Carvedilol—CYP2E1—medulla oblongata—malignant glioma	0.000164	0.00219	CbGeAlD
Carvedilol—Asthenia—Carmustine—malignant glioma	0.000162	0.00244	CcSEcCtD
Carvedilol—Hypersensitivity—Temozolomide—malignant glioma	0.000161	0.00242	CcSEcCtD
Carvedilol—ADRB1—brain—malignant glioma	0.00016	0.00214	CbGeAlD
Carvedilol—ADRA1A—central nervous system—malignant glioma	0.00016	0.00213	CbGeAlD
Carvedilol—Asthenia—Temozolomide—malignant glioma	0.000157	0.00236	CcSEcCtD
Carvedilol—ADRA1A—cerebellum—malignant glioma	0.000156	0.00208	CbGeAlD
Carvedilol—Diarrhoea—Carmustine—malignant glioma	0.000155	0.00233	CcSEcCtD
Carvedilol—Pruritus—Temozolomide—malignant glioma	0.000155	0.00233	CcSEcCtD
Carvedilol—KCNH2—central nervous system—malignant glioma	0.000154	0.00206	CbGeAlD
Carvedilol—ADRA2A—midbrain—malignant glioma	0.000154	0.00205	CbGeAlD
Carvedilol—ADRA2C—central nervous system—malignant glioma	0.000152	0.00203	CbGeAlD
Carvedilol—KCNH2—cerebellum—malignant glioma	0.000151	0.00201	CbGeAlD
Carvedilol—ADRA2A—spinal cord—malignant glioma	0.00015	0.002	CbGeAlD
Carvedilol—Dizziness—Carmustine—malignant glioma	0.00015	0.00225	CcSEcCtD
Carvedilol—Diarrhoea—Temozolomide—malignant glioma	0.00015	0.00225	CcSEcCtD
Carvedilol—ADRA2C—cerebellum—malignant glioma	0.000149	0.00199	CbGeAlD
Carvedilol—CYP2E1—spinal cord—malignant glioma	0.000147	0.00196	CbGeAlD
Carvedilol—ABCB1—embryo—malignant glioma	0.000146	0.00196	CbGeAlD
Carvedilol—Dizziness—Temozolomide—malignant glioma	0.000145	0.00217	CcSEcCtD
Carvedilol—Vomiting—Carmustine—malignant glioma	0.000144	0.00216	CcSEcCtD
Carvedilol—Rash—Carmustine—malignant glioma	0.000143	0.00214	CcSEcCtD
Carvedilol—Dermatitis—Carmustine—malignant glioma	0.000143	0.00214	CcSEcCtD
Carvedilol—Headache—Carmustine—malignant glioma	0.000142	0.00213	CcSEcCtD
Carvedilol—PTGS1—spinal cord—malignant glioma	0.000141	0.00188	CbGeAlD
Carvedilol—Vomiting—Temozolomide—malignant glioma	0.000139	0.00209	CcSEcCtD
Carvedilol—Rash—Temozolomide—malignant glioma	0.000138	0.00207	CcSEcCtD
Carvedilol—Dermatitis—Temozolomide—malignant glioma	0.000138	0.00207	CcSEcCtD
Carvedilol—Headache—Temozolomide—malignant glioma	0.000137	0.00206	CcSEcCtD
Carvedilol—Nausea—Carmustine—malignant glioma	0.000134	0.00202	CcSEcCtD
Carvedilol—CYP1A1—central nervous system—malignant glioma	0.00013	0.00174	CbGeAlD
Carvedilol—Nausea—Temozolomide—malignant glioma	0.00013	0.00195	CcSEcCtD
Carvedilol—ABCB1—retina—malignant glioma	0.000129	0.00173	CbGeAlD
Carvedilol—ADRA1A—brain—malignant glioma	0.000127	0.00169	CbGeAlD
Carvedilol—KCNH2—brain—malignant glioma	0.000123	0.00164	CbGeAlD
Carvedilol—ADRA2A—central nervous system—malignant glioma	0.000122	0.00162	CbGeAlD
Carvedilol—ADRA2C—brain—malignant glioma	0.000121	0.00161	CbGeAlD
Carvedilol—ABCB1—telencephalon—malignant glioma	0.000119	0.00159	CbGeAlD
Carvedilol—CYP2E1—central nervous system—malignant glioma	0.000119	0.00159	CbGeAlD
Carvedilol—ADRA2A—cerebellum—malignant glioma	0.000119	0.00159	CbGeAlD
Carvedilol—CYP2E1—cerebellum—malignant glioma	0.000116	0.00155	CbGeAlD
Carvedilol—PTGS1—central nervous system—malignant glioma	0.000115	0.00153	CbGeAlD
Carvedilol—CYP1A1—brain—malignant glioma	0.000103	0.00138	CbGeAlD
Carvedilol—ADRA2A—brain—malignant glioma	9.65e-05	0.00129	CbGeAlD
Carvedilol—CYP3A4—central nervous system—malignant glioma	9.56e-05	0.00128	CbGeAlD
Carvedilol—CYP2E1—brain—malignant glioma	9.44e-05	0.00126	CbGeAlD
Carvedilol—CYP2D6—central nervous system—malignant glioma	9.41e-05	0.00126	CbGeAlD
Carvedilol—ABCB1—medulla oblongata—malignant glioma	9.36e-05	0.00125	CbGeAlD
Carvedilol—CYP2D6—cerebellum—malignant glioma	9.2e-05	0.00123	CbGeAlD
Carvedilol—PTGS1—brain—malignant glioma	9.09e-05	0.00121	CbGeAlD
Carvedilol—ABCB1—midbrain—malignant glioma	8.55e-05	0.00114	CbGeAlD
Carvedilol—ABCB1—spinal cord—malignant glioma	8.35e-05	0.00111	CbGeAlD
Carvedilol—CYP2D6—brain—malignant glioma	7.47e-05	0.000997	CbGeAlD
Carvedilol—ABCB1—central nervous system—malignant glioma	6.77e-05	0.000904	CbGeAlD
Carvedilol—ABCB1—cerebellum—malignant glioma	6.62e-05	0.000883	CbGeAlD
Carvedilol—ABCB1—brain—malignant glioma	5.37e-05	0.000717	CbGeAlD
Carvedilol—ADRA1D—Signaling Pathways—IL2—malignant glioma	1.82e-06	1.36e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—MDM2—malignant glioma	1.82e-06	1.36e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—ERBB2—malignant glioma	1.82e-06	1.36e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—NOTCH1—malignant glioma	1.82e-06	1.36e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—RAF1—malignant glioma	1.81e-06	1.35e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—FGF2—malignant glioma	1.81e-06	1.35e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—PIK3CB—malignant glioma	1.81e-06	1.35e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—TP53—malignant glioma	1.8e-06	1.34e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—BRAF—malignant glioma	1.8e-06	1.34e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—TP53—malignant glioma	1.79e-06	1.34e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—ERBB2—malignant glioma	1.79e-06	1.34e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—PIK3CB—malignant glioma	1.79e-06	1.34e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—PTGS1—malignant glioma	1.79e-06	1.34e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—CD80—malignant glioma	1.78e-06	1.33e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—PIK3CG—malignant glioma	1.78e-06	1.33e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—APC—malignant glioma	1.78e-06	1.33e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—PPARG—malignant glioma	1.77e-06	1.33e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—PIK3CB—malignant glioma	1.77e-06	1.32e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—EGF—malignant glioma	1.75e-06	1.31e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—AKT2—malignant glioma	1.75e-06	1.31e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—PTPN11—malignant glioma	1.74e-06	1.3e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—malignant glioma	1.74e-06	1.3e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—EGFR—malignant glioma	1.74e-06	1.3e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—CXCL8—malignant glioma	1.74e-06	1.3e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—PTEN—malignant glioma	1.73e-06	1.29e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—PIK3CA—malignant glioma	1.73e-06	1.29e-05	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—PTEN—malignant glioma	1.73e-06	1.29e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—MMP9—malignant glioma	1.73e-06	1.29e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—CXCL8—malignant glioma	1.72e-06	1.29e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—MDM2—malignant glioma	1.72e-06	1.29e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—GSTP1—malignant glioma	1.72e-06	1.28e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—PTEN—malignant glioma	1.72e-06	1.28e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—RAF1—malignant glioma	1.72e-06	1.28e-05	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—PIK3CD—malignant glioma	1.71e-06	1.28e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—CXCL8—malignant glioma	1.7e-06	1.27e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—PIK3CA—malignant glioma	1.7e-06	1.27e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—ERBB2—malignant glioma	1.7e-06	1.27e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—MDM2—malignant glioma	1.69e-06	1.27e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—RAF1—malignant glioma	1.69e-06	1.26e-05	CbGpPWpGaD
Carvedilol—ADRB1—GPCR downstream signaling—AKT1—malignant glioma	1.68e-06	1.26e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—PIK3CD—malignant glioma	1.68e-06	1.26e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—PIK3CB—malignant glioma	1.67e-06	1.25e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling by GPCR—AKT1—malignant glioma	1.67e-06	1.25e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—CAT—malignant glioma	1.67e-06	1.25e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—ERBB2—malignant glioma	1.67e-06	1.25e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—BRAF—malignant glioma	1.67e-06	1.25e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—BCHE—malignant glioma	1.67e-06	1.24e-05	CbGpPWpGaD
Carvedilol—ADRA2B—GPCR downstream signaling—AKT1—malignant glioma	1.66e-06	1.24e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—CASP3—malignant glioma	1.66e-06	1.24e-05	CbGpPWpGaD
Carvedilol—ADRA1A—GPCR downstream signaling—PIK3CA—malignant glioma	1.66e-06	1.24e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—IL2—malignant glioma	1.66e-06	1.24e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—CASP3—malignant glioma	1.65e-06	1.23e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—PIK3CB—malignant glioma	1.65e-06	1.23e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—IL2—malignant glioma	1.65e-06	1.23e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—SLC5A5—malignant glioma	1.65e-06	1.23e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—KRAS—malignant glioma	1.64e-06	1.23e-05	CbGpPWpGaD
Carvedilol—ADRB2—GPCR downstream signaling—AKT1—malignant glioma	1.64e-06	1.23e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—CASP3—malignant glioma	1.63e-06	1.22e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—PIK3CB—malignant glioma	1.63e-06	1.22e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—IL2—malignant glioma	1.63e-06	1.21e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—AKT2—malignant glioma	1.62e-06	1.21e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—EGFR—malignant glioma	1.62e-06	1.21e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—PIK3CD—malignant glioma	1.62e-06	1.21e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—PTGS2—malignant glioma	1.61e-06	1.2e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—CAV1—malignant glioma	1.61e-06	1.2e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—CXCL8—malignant glioma	1.61e-06	1.2e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—FGF2—malignant glioma	1.61e-06	1.2e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—CXCL8—malignant glioma	1.58e-06	1.18e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—NCOR1—malignant glioma	1.58e-06	1.18e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—MMP9—malignant glioma	1.57e-06	1.18e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—PTEN—malignant glioma	1.56e-06	1.17e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—PIK3CD—malignant glioma	1.56e-06	1.17e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—MMP9—malignant glioma	1.56e-06	1.16e-05	CbGpPWpGaD
Carvedilol—ADRA2C—GPCR downstream signaling—AKT1—malignant glioma	1.55e-06	1.16e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—VEGFA—malignant glioma	1.55e-06	1.16e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—PTEN—malignant glioma	1.55e-06	1.16e-05	CbGpPWpGaD
Carvedilol—ADRA2A—GPCR downstream signaling—PIK3CA—malignant glioma	1.55e-06	1.16e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—CASP3—malignant glioma	1.54e-06	1.15e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—MMP9—malignant glioma	1.54e-06	1.15e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—IL2—malignant glioma	1.54e-06	1.15e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—STAT3—malignant glioma	1.53e-06	1.15e-05	CbGpPWpGaD
Carvedilol—ADRA1B—GPCR downstream signaling—AKT1—malignant glioma	1.53e-06	1.14e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—PTEN—malignant glioma	1.53e-06	1.14e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—KRAS—malignant glioma	1.53e-06	1.14e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—AKT1—malignant glioma	1.53e-06	1.14e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—CAV1—malignant glioma	1.52e-06	1.13e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—AKT1—malignant glioma	1.52e-06	1.13e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—CASP3—malignant glioma	1.52e-06	1.13e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—AKT1—malignant glioma	1.51e-06	1.13e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—IL2—malignant glioma	1.51e-06	1.13e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—AKT1—malignant glioma	1.51e-06	1.13e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—PIK3CA—malignant glioma	1.51e-06	1.13e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—CAV1—malignant glioma	1.51e-06	1.13e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—MDM2—malignant glioma	1.5e-06	1.12e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—RAF1—malignant glioma	1.5e-06	1.12e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—FGF2—malignant glioma	1.49e-06	1.12e-05	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—PIK3CB—malignant glioma	1.49e-06	1.12e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—AKT1—malignant glioma	1.49e-06	1.12e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—ERBB2—malignant glioma	1.48e-06	1.11e-05	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—PTGS2—malignant glioma	1.48e-06	1.11e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—PIK3CG—malignant glioma	1.47e-06	1.1e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—PIK3CB—malignant glioma	1.46e-06	1.09e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—MMP9—malignant glioma	1.46e-06	1.09e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—PTEN—malignant glioma	1.45e-06	1.08e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	1.44e-06	1.07e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—MMP9—malignant glioma	1.43e-06	1.07e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—MYC—malignant glioma	1.43e-06	1.07e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—PTEN—malignant glioma	1.42e-06	1.06e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—PPARG—malignant glioma	1.42e-06	1.06e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—VEGFA—malignant glioma	1.41e-06	1.06e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—AKT1—malignant glioma	1.41e-06	1.06e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—PIK3CB—malignant glioma	1.41e-06	1.05e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—CXCL8—malignant glioma	1.41e-06	1.05e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—PTEN—malignant glioma	1.41e-06	1.05e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—PIK3CA—malignant glioma	1.4e-06	1.05e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—VEGFA—malignant glioma	1.4e-06	1.05e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—STAT3—malignant glioma	1.4e-06	1.04e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—MDM2—malignant glioma	1.4e-06	1.04e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—PTGS2—malignant glioma	1.4e-06	1.04e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—EGFR—malignant glioma	1.39e-06	1.04e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—RAF1—malignant glioma	1.39e-06	1.04e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—AKT1—malignant glioma	1.39e-06	1.04e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—STAT3—malignant glioma	1.39e-06	1.04e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—PIK3CG—malignant glioma	1.38e-06	1.03e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—VEGFA—malignant glioma	1.38e-06	1.03e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—ERBB2—malignant glioma	1.38e-06	1.03e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—PIK3CG—malignant glioma	1.37e-06	1.02e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—STAT3—malignant glioma	1.37e-06	1.02e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—PIK3CB—malignant glioma	1.36e-06	1.02e-05	CbGpPWpGaD
Carvedilol—ADRA1A—GPCR downstream signaling—AKT1—malignant glioma	1.36e-06	1.02e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—CASP3—malignant glioma	1.35e-06	1.01e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—IL2—malignant glioma	1.34e-06	1e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—PPARG—malignant glioma	1.34e-06	9.98e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—GSTP1—malignant glioma	1.33e-06	9.91e-06	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—PPARG—malignant glioma	1.32e-06	9.89e-06	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—KRAS—malignant glioma	1.32e-06	9.85e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—CXCL8—malignant glioma	1.31e-06	9.77e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—VEGFA—malignant glioma	1.31e-06	9.77e-06	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—MYC—malignant glioma	1.3e-06	9.71e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—STAT3—malignant glioma	1.29e-06	9.67e-06	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—PTEN—malignant glioma	1.29e-06	9.65e-06	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—PIK3CD—malignant glioma	1.29e-06	9.64e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—CAT—malignant glioma	1.29e-06	9.64e-06	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—MYC—malignant glioma	1.29e-06	9.62e-06	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—CAV1—malignant glioma	1.29e-06	9.62e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—VEGFA—malignant glioma	1.29e-06	9.61e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—STAT3—malignant glioma	1.27e-06	9.52e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—MMP9—malignant glioma	1.27e-06	9.51e-06	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—MYC—malignant glioma	1.27e-06	9.5e-06	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—EGFR—malignant glioma	1.27e-06	9.5e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—PTEN—malignant glioma	1.27e-06	9.45e-06	CbGpPWpGaD
Carvedilol—ADRA2A—GPCR downstream signaling—AKT1—malignant glioma	1.26e-06	9.44e-06	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—EGFR—malignant glioma	1.26e-06	9.41e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—CASP3—malignant glioma	1.25e-06	9.35e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—IL2—malignant glioma	1.25e-06	9.34e-06	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—EGFR—malignant glioma	1.24e-06	9.29e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—AKT1—malignant glioma	1.23e-06	9.22e-06	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	1.23e-06	9.19e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—PIK3CA—malignant glioma	1.22e-06	9.12e-06	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—PIK3CA—malignant glioma	1.22e-06	9.11e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—NCOR1—malignant glioma	1.22e-06	9.1e-06	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—PTEN—malignant glioma	1.22e-06	9.09e-06	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—PIK3CD—malignant glioma	1.22e-06	9.09e-06	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—PIK3CA—malignant glioma	1.21e-06	9.05e-06	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—PIK3CD—malignant glioma	1.21e-06	9.01e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—MYC—malignant glioma	1.2e-06	8.99e-06	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—KRAS—malignant glioma	1.2e-06	8.97e-06	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—KRAS—malignant glioma	1.19e-06	8.89e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—MYC—malignant glioma	1.18e-06	8.84e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—MMP9—malignant glioma	1.18e-06	8.84e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—EGFR—malignant glioma	1.18e-06	8.79e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—PTEN—malignant glioma	1.18e-06	8.78e-06	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—KRAS—malignant glioma	1.17e-06	8.78e-06	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—PIK3CG—malignant glioma	1.17e-06	8.76e-06	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—TP53—malignant glioma	1.17e-06	8.75e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—EGFR—malignant glioma	1.16e-06	8.65e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—AKT1—malignant glioma	1.15e-06	8.57e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—VEGFA—malignant glioma	1.14e-06	8.54e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—STAT3—malignant glioma	1.13e-06	8.46e-06	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—PPARG—malignant glioma	1.13e-06	8.45e-06	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—PIK3CB—malignant glioma	1.12e-06	8.41e-06	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—PTGS2—malignant glioma	1.11e-06	8.33e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—KRAS—malignant glioma	1.11e-06	8.3e-06	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—PIK3CA—malignant glioma	1.1e-06	8.24e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—KRAS—malignant glioma	1.09e-06	8.17e-06	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—PIK3CA—malignant glioma	1.09e-06	8.17e-06	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—PIK3CA—malignant glioma	1.08e-06	8.06e-06	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—TP53—malignant glioma	1.07e-06	7.97e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—VEGFA—malignant glioma	1.06e-06	7.93e-06	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—PIK3CB—malignant glioma	1.06e-06	7.92e-06	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—TP53—malignant glioma	1.06e-06	7.9e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—MYC—malignant glioma	1.05e-06	7.86e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—STAT3—malignant glioma	1.05e-06	7.86e-06	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—PIK3CB—malignant glioma	1.05e-06	7.85e-06	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—PTGS2—malignant glioma	1.05e-06	7.85e-06	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—TP53—malignant glioma	1.04e-06	7.8e-06	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—PTGS2—malignant glioma	1.04e-06	7.78e-06	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—PIK3CD—malignant glioma	1.03e-06	7.7e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—EGFR—malignant glioma	1.03e-06	7.68e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—PIK3CA—malignant glioma	1.02e-06	7.63e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—PIK3CA—malignant glioma	1e-06	7.51e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—AKT1—malignant glioma	9.97e-07	7.45e-06	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—AKT1—malignant glioma	9.95e-07	7.44e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—CAV1—malignant glioma	9.93e-07	7.42e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—PIK3CA—malignant glioma	9.92e-07	7.41e-06	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—AKT1—malignant glioma	9.89e-07	7.39e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—TP53—malignant glioma	9.88e-07	7.38e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—MYC—malignant glioma	9.77e-07	7.3e-06	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—PTEN—malignant glioma	9.72e-07	7.26e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—TP53—malignant glioma	9.72e-07	7.26e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—KRAS—malignant glioma	9.71e-07	7.26e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—EGFR—malignant glioma	9.55e-07	7.14e-06	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—PTEN—malignant glioma	9.16e-07	6.85e-06	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—PIK3CA—malignant glioma	9.11e-07	6.81e-06	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—PTEN—malignant glioma	9.08e-07	6.79e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—PIK3CG—malignant glioma	9.04e-07	6.76e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—KRAS—malignant glioma	9.03e-07	6.74e-06	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—AKT1—malignant glioma	9.01e-07	6.73e-06	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—PIK3CB—malignant glioma	8.98e-07	6.71e-06	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—AKT1—malignant glioma	8.93e-07	6.67e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—PIK3CA—malignant glioma	8.92e-07	6.67e-06	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—PTGS2—malignant glioma	8.9e-07	6.65e-06	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—AKT1—malignant glioma	8.81e-07	6.59e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—PPARG—malignant glioma	8.73e-07	6.52e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—TP53—malignant glioma	8.63e-07	6.45e-06	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—PIK3CA—malignant glioma	8.59e-07	6.42e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—AKT1—malignant glioma	8.34e-07	6.23e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—PIK3CA—malignant glioma	8.29e-07	6.2e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—AKT1—malignant glioma	8.21e-07	6.13e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—AKT1—malignant glioma	8.1e-07	6.05e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—TP53—malignant glioma	8.02e-07	5.99e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—PIK3CD—malignant glioma	7.95e-07	5.94e-06	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—PTEN—malignant glioma	7.76e-07	5.8e-06	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—AKT1—malignant glioma	7.44e-07	5.56e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—AKT1—malignant glioma	7.29e-07	5.45e-06	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—AKT1—malignant glioma	7.01e-07	5.24e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—PIK3CB—malignant glioma	6.93e-07	5.18e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—PTGS2—malignant glioma	6.87e-07	5.13e-06	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—PIK3CA—malignant glioma	6.86e-07	5.12e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—AKT1—malignant glioma	6.77e-07	5.06e-06	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—PIK3CA—malignant glioma	6.46e-07	4.83e-06	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—PIK3CA—malignant glioma	6.41e-07	4.79e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—PTEN—malignant glioma	5.99e-07	4.48e-06	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—AKT1—malignant glioma	5.6e-07	4.19e-06	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—PIK3CA—malignant glioma	5.47e-07	4.09e-06	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—AKT1—malignant glioma	5.28e-07	3.94e-06	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—AKT1—malignant glioma	5.23e-07	3.91e-06	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—AKT1—malignant glioma	4.47e-07	3.34e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—PIK3CA—malignant glioma	4.22e-07	3.16e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—AKT1—malignant glioma	3.45e-07	2.58e-06	CbGpPWpGaD
